MARKET

TRAW

TRAW

Traws Pharma
NASDAQ
1.400
0.000
0.00%
Opening 09:40 12/18 EST
OPEN
1.420
PREV CLOSE
1.400
HIGH
1.470
LOW
1.390
VOLUME
74.47K
TURNOVER
--
52 WEEK HIGH
19.44
52 WEEK LOW
0.9700
MARKET CAP
11.19M
P/E (TTM)
0.0496
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 22h ago
Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid
Benzinga · 1d ago
Promising Phase 2 Results for Ratutrelvir Highlight Clinical and Market Differentiation in COVID-19 Treatment
TipRanks · 1d ago
Traws Pharma Reports Positive Phase 2 Trial Results
TipRanks · 1d ago
Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid
TipRanks · 1d ago
Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026
Benzinga · 1d ago
Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients
Reuters · 1d ago
TRAWS PHARMA INC: FINAL DATA ANALYSIS TO BE REPORTED IN JANUARY 2026
Reuters · 1d ago
More
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Webull offers Traws Pharma Inc stock information, including NASDAQ: TRAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRAW stock methods without spending real money on the virtual paper trading platform.